Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3499)	11/7/2002 10:14:10 PM
From: scaram(o)uche	Respond to of 10345

the strategy................. inexpharm.com some background............. inexpharm.com a recent status update from a release.............. INEX and Elan Corporation, plc are in discussions on an agreement to return complete control and ownership of Onco TCS to INEX. INEX has also begun negotiations with several companies that are candidates to become the new partner for the commercialization of Onco TCS. These events were prompted by Elan’s intention, announced in mid 2002, to withdraw from oncology and focus its business on three therapeutic areas – neurology, pain management and autoimmune disease. (snip) INEX and Elan are currently in discussions regarding the potential acquisition by INEX of Elan’s 19.9% interest in the joint venture company formed to develop Onco TCS. This potential acquisition would result in a termination of Elan’s on-going 19.9% funding obligation with respect to Onco TCS development costs. Included in the negotiated terms for the potential acquisition of Elan’s interest in the joint venture company would be an agreed cut-off point on Elan’s 19.9% funding of Onco TCS development costs. a comment............ a 100% response rate is expected. IMO, this release provides absolutely no information of relevance. I'm posting it, with this comment, in hopes that an oncologist can correct me. Inex Pharmaceuticals Abstract for First-line Lymphoma Combination Therapy Accepted for Presentation at American Society of Hematology Conference For immediate release: Nov 07, 2002 VANCOUVER - Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that an abstract on the company’s lead product, Onco TCS, has been accepted for presentation at the American Society of Hematology (ASH) annual meeting being held in Philadelphia December 6-10, 2002. The abstracts have been made available on the ASH website at www.hematology.org. The abstract was accepted on the first 66 evaluable patients that have completed treatment in a Phase II clinical trial evaluating Onco TCS as a first-line treatment for aggressive non-Hodgkin’s lymphoma (NHL). All 66 patients responded to therapy for an overall response rate of 100%. Of the 66 patients, 65 (98%) completely responded to therapy and had all of their tumors eliminated and one patient (2%) partially responded to therapy and had their tumor volume decreased by more than 50%. The trial is being conducted at The University of Texas M. D. Anderson Cancer Center in Houston. Dr. Alma Rodriguez, the trial’s Principle Investigator, will give a full presentation of updated data at the ASH meeting on December 9, 2002. The current standard first-line treatment for the aggressive form of NHL is the CHOP chemotherapy combination, comprising the drugs cyclophosphamide, doxorubicin hydrochloride, Oncovin® (vincristine) and prednisone. The INEX trial is treating NHL patients with CHOP in which the Oncovin® (vincristine) component is substituted with Onco TCS, which is vincristine encapsulated inside INEX’s proprietary liposomal drug delivery technology, Transmembrane Carrier System (TCS). Patients diagnosed with B-cell lymphoma also receive Rituxan® (rituximab), a monoclonal antibody, as recently published results support its investigational use with CHOP. Onco TCS is being evaluated in nine other human clinical trials for several cancers, including a pivotal Phase II/III trial for the treatment of relapsed aggressive NHL designed to provide the data required to file in 2003 a New Drug Application (NDA) for marketing approval with the United States Food and Drug Administration (FDA). The pivotal Phase II/III clinical trial results will be released in late November or early December. NHL is the fifth-leading cause of cancer deaths in Canada (2,800 estimated in 2002) and the sixth-leading cause of cancer deaths in the United States (24,400 estimated in 2002), according to estimates of the national cancer institutes in Canada and the U.S. Approximately 60,000 new cases will be diagnosed in Canada and the U.S. in 2002. The number of cases of NHL diagnosed in the U.S. has increased by about 50% during the last 15 years. INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer. INEX investor contact: Ian Mortimer Director, Investor Relations Inex Pharmaceuticals Corp. Tel: 604.419.3200 Email: info@inexpharm.com Website: www.inexpharm.com INEX media contact: Maria LoScerbo James Hoggan & Associates Inc. Tel: 604.739.7500 Email: mloscerbo@hoggan.com INEX’s common shares are traded on the Toronto Stock Exchange under the trading symbol “IEX”. Rituxan® is a registered U.S. trademark of IDEC Pharmaceuticals Inc.